Rare Thyroid Therapeutics is a privately held, clinical stage research and development company, located in Stockholm, Sweden. We are specialized in the development of therapies for rare thyroid signalling disorders, a disease area which is currently underserved and where there is a significant unmet medical need, without available therapies. Our team holds considerable experience from the rare and orphan space and have been involved in several successful companies and development projects within the field, including Swedish Orphan (Sobi), OxThera, Medical Need and Wilson Therapeutics.
Our collaboration with Erasmus Medical Center in Rotterdam to develop the first cure for MCT8 deficiency was in 2017 selected for a three-year EU grant within the EUREKA EUROSTARS framework
Peder holds extensive experience from development and commercialization of orphan drugs, both on an operative and board level. Peder’s background includes being the founder and CEO of Medical Neeed Europe and EVP Business Development and Strategy at Sobi and Swedish Orphan. Peder has previously served as a director of the board of Wilson Therapeutics and OxThera and is currently on the board of Immedica. Peder is a registered physician with an MD from Uppsala University, a BSc in International Economics and Business Administration from the same university and has a background as a management consultant with the Boston Consulting Group, focusing primarily on the life sciences sector.